Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result
Prostate cancer mortality after a benign systematic TRUS-guided biopsy is low. In these patients, PSAD predicts prostate cancer mortality and provides additional value to other clinical variables. PSAD-based stratification can be used to guide follow-up strategy.
Authors
- Kirsi Talala (ORCID: https://orcid.org/0000-0002-9705-9265)
- Jani Raitanen (ORCID: https://orcid.org/0000-0001-7674-0978)
- Anssi Auvinen (ORCID: https://orcid.org/0000-0003-1125-4818)
- Antti Rannikko (ORCID: https://orcid.org/0000-0002-4261-3484)
- Juho Pylväläinen (ORCID: https://orcid.org/0000-0003-3192-3759)
Institutions
- University of Helsinki (FI)
- Tampere University (FI)
- Helsinki University Hospital (FI)
- Cancer Society of Finland (FI)
- Urho Kaleva Kekkonen Institute (FI)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1111/bju.16641
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Jane ja Aatos Erkon Säätiö
- Syöpäsäätiö